Methylation epigenotypes and genetic features in colorectal laterally spreading tumors

International Journal of Cancer

Volumn 135, Issue 7, 2014, Pages 1586-1595

  Sakai, Eiji ^a,b   Ohata, Ken ^c   Chiba, Hideyuki ^c   Matsuhashi, Nobuyuki ^c   Doi, Noriteru ^c   Fukushima, Junichi ^c   Endo, Hiroki ^a   Takahashi, Hirokazu ^a   Tsuji, Shingo ^d   Yagi, Koichi ^d   Matsusaka, Keisuke ^b   Aburatani, Hiroyuki ^d   Nakajima, Atsushi ^a   Kaneda, Atsushi ^b,d,e  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

colorectal cancer; DNA methylation; KRAS; laterally spreading tumor (LST); TP53

Indexed keywords

B RAF KINASE; DNA; K RAS PROTEIN; PROTEIN P53;

AGED; ARTICLE; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; ENDOSCOPIC SURGERY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; ONCOGENE K RAS; PRIORITY JOURNAL; PYROSEQUENCING; QUANTITATIVE ANALYSIS;

COLORECTAL CANCER; DNA METHYLATION; KRAS; LATERALLY SPREADING TUMOR (LST); TP53;

ADENOMA; AGED; BETA CATENIN; COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENOMICS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84904503891     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28814     Document Type: Article

References (50)

1. Grady WM, Carethers JM,. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135: 1079-99.
2. Jones PA, Baylin SB,. The epigenomics of cancer. Cell 2007; 128: 683-92.
3. Kaneda A, Feinberg AP,. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res 2005; 65: 11236-40.
4. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32.
5. Seshagiri S, Stawiski EW, Durinck S, et al. Recurrent R-spondin fusions in colon cancer. Nature 2012; 488: 660-4.
6. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
7. Feinberg AP, Ohlsson R, Henikoff S,. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21-33.
8. Kaneda A, Yagi K,. Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. Cancer Sci 2010; 102: 18-24.
9. Yagi K, Akagi K, Hayashi H, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 2010; 16: 21-33.
10. Ogino S, Kawasaki T, Kirkner GJ, et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006; 8: 582-8.
11. Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007; 104: 18654-9.
12. Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22: 271-82.
13. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-6.
14. Yagi K, Takahashi H, Akagi K, et al. Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma. Am J Pathol 2012; 180: 616-25.
15. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004; 53: 1137-44.
16. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-93.
17. Iwase T, Kushima R, Mukaisho K, et al. Overexpression of CD10 and reduced MUC2 expression correlate with the development and progression of colorectal neoplasms. Pathol Res Pract 2005; 201: 83-91.
18. Muto T, Kamiya J, Sawada T, et al. Small "flat adenoma" of the large bowel with special reference to its clinicopathologic features. Dis Colon Rectum 1985; 28: 847-51.
19. Minamoto T, Sawaguchi K, Ohta T, et al. Superficial-type adenomas and adenocarcinomas of the colon and rectum: a comparative morphological study. Gastroenterology 1994; 106: 1436-43.
20. Tada S, Iida M, Matsumoto T, et al. Small flat cancer of the rectum: clinicopathologic and endoscopic features. Gastrointest Endosc 1995; 42: 109-13.
21. Watari J, Saitoh Y, Obara T, et al. Natural history of colorectal nonpolypoid adenomas: a prospective colonoscopic study and relation with cell kinetics and K-ras mutations. Am J Gastroenterol 2002; 97: 2109-15.
22. Kudo S, Kashida H, Nakajima T, et al. Endoscopic diagnosis and treatment of early colorectal cancer. World J Surg 1997; 21: 694-701.
23. Rembacken BJ, Fujii T, Cairns A, et al. Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK. Lancet 2000; 355: 1211-14.
24. Soetikno R, Friedland S, Kaltenbach T, et al. Nonpolypoid (flat and depressed) colorectal neoplasms. Gastroenterology 2006; 130: 566-76.
25. Minamoto T, Sawaguchi K, Mai M, et al. Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas. Cancer Res 1994; 54: 2841-4.
26. Morita T, Tomita N, Ohue M, et al. Molecular analysis of diminutive, flat, depressed colorectal lesions: are they precursors of polypoid adenoma or early stage carcinoma? Gastrointest Endosc 2002; 56: 663-71.
27. Saitoh Y, Waxman I, West AB, et al. Prevalence and distinctive biologic features of flat colorectal adenomas in a North American population. Gastroenterology 2001; 120: 1657-65.
28. Yashiro M, Carethers JM, Laghi L, et al. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res 2001; 61: 2676-83.
29. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-5.
30. Kawasaki T, Nosho K, Ohnishi M, et al. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia 2007; 9: 569-77.
31. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-90.
32. Iida S, Kato S, Ishiguro M, et al. PIK3CA mutation and methylation influences the outcome of colorectal cancer. Oncol Lett 2012; 3: 565-70.
33. Matsusaka K, Kaneda A, Nagae G, et al. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res 2011; 71: 7187-97.
34. Hiraoka S, Kato J, Tatsukawa M, et al. Laterally spreading type of colorectal adenoma exhibits a unique methylation phenotype and K-ras mutations. Gastroenterology 2006; 131: 379-89.
35. Hashimoto K, Shimizu Y, Suehiro Y, et al. Hypermethylation status of APC inversely correlates with the presence of submucosal invasion in laterally spreading colorectal tumors. Mol Carcinog 2008; 47: 1-8.
36. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006; 55: 1000-6.
37. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61: 847-54.
38. Rosty C, Young JP, Walsh MD, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One 2013; 8: e65479.
39. Clevers H,. Wnt breakers in colon cancer. Cancer Cell 2004; 5: 5-6.
40. Wong NA, Pignatelli M,. Beta-catenin-a linchpin in colorectal carcinogenesis? Am J Pathol 2002; 160: 389-401.
41. Kobayashi M, Honma T, Matsuda Y, et al. Nuclear translocation of beta-catenin in colorectal cancer. Br J Cancer 2000; 82: 1689-93.
42. Wong SC, Lo ES, Lee KC, et al. Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 2004; 10: 1401-8.
43. Sugimoto T, Ohta M, Ikenoue T, et al. Macroscopic morphologic subtypes of laterally spreading colorectal tumors showing distinct molecular alterations. Int J Cancer 2010; 127: 1562-9.
44. Schubbert S, Shannon K, Bollag G,. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
45. Normanno N, Tejpar S, Morgillo F, et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519-27.
46. Worthley DL, Whitehall VL, Spring KJ, et al. Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol 2007; 13: 3784-91.
47. Whitehall VL, Rickman C, Bond CE, et al. Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer 2012; 131: 813-20.
48. Rotondano G, Bianco MA, Buffoli F, et al. The Cooperative Italian FLIN Study Group: prevalence and clinico-pathological features of colorectal laterally spreading tumors. Endoscopy 2011; 43: 856-61.
49. Winawer SJ, Zauber AG, Fletcher RH, et al.; US Multi-Society Task Force on Colorectal Cancer; American Cancer Society. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130: 1872-85.
50. Goto H, Oda Y, Murakami Y, et al. Proportion of de novo cancers among colorectal cancers in Japan. Gastroenterology 2006; 131: 40-6.